{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.74","upperLimit":"1.81","value":"1.78"},{"groupId":"OG001","lowerLimit":"1.35","upperLimit":"3.52","value":"1.64"},{"comment":"Median and upper limit of 95% confidence interval (CI) was not estimable due to low number of participants with events.","groupId":"OG002","lowerLimit":"9.51","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG003","lowerLimit":"0.46","upperLimit":"NA","value":"1.76"},{"comment":"Upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG004","lowerLimit":"0.59","upperLimit":"NA","value":"2.55"},{"groupId":"OG005","lowerLimit":"1.78","upperLimit":"2.04","value":"1.88"},{"groupId":"OG006","lowerLimit":"1.68","upperLimit":"3.52","value":"1.88"},{"groupId":"OG007","lowerLimit":"1.78","upperLimit":"9.08","value":"3.62"},{"groupId":"OG008","lowerLimit":"1.78","upperLimit":"2.63","value":"1.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"58"},{"groupId":"OG006","value":"29"},{"groupId":"OG007","value":"31"},{"groupId":"OG008","value":"33"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the first documented progressive disease per RECIST v1.1 or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Colorectal Cancer received epacadostat 100 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG000","title":"Phase 2: Epacadostat 100 mg + Nivolumab 240 in Colorectal Cancer"},{"description":"Participants with DLBCL received epacadostat 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG001","title":"Phase 2: Epacadostat 300 mg + Nivolumab 240 mg in DLBCL"},{"description":"Participants with Melanoma(I/O Naive) received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG002","title":"Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg in Melanoma(I/O Naive)"},{"description":"Participants with Melanoma (I/O Relapsed) received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG003","title":"Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Relapsed)"},{"description":"Participants with Melanoma (I/O Refractory) received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG004","title":"Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Refractory)"},{"description":"Participants with NSCLC received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG005","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in NSCLC"},{"description":"Participants with Ovarian Cancer received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG006","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Ovarian Cancer"},{"description":"Participants with SCCHN received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG007","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in SCCHN"},{"description":"Participants with Glioblastoma received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG008","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Glioblastoma"}],"paramType":"MEDIAN","populationDescription":"The Phase 2 Full Analysis Population includes all participants enrolled in the study who take at least 1 dose of study drug. The data is reported per cancer type in this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose up end of the study (up to approximately 6 years)","title":"Phase 2: Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}